Jazz Pharmaceuticals (JAZZ) Receivables (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Receivables of $836.3 million for Q1 2026, up 28.07% year-over-year from $653.0 million in Q1 2025, and up 0.67% quarter-over-quarter from $830.7 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Receivables (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Receivables history runs 17 years deep, the most recent figure standing at $836.3 million for Q1 2026.
- In Q1 2026, Receivables rose 28.07% year-over-year to $836.3 million; the TTM figure through Mar 2026 stood at $836.3 million (up 28.07% YoY), while the FY2025 annual figure was $830.7 million, up 15.9% from the prior year.
- Receivables for Q1 2026 stood at $836.3 million, up from $830.7 million in the prior quarter.
- The five-year high for Receivables was $836.3 million in Q1 2026, with the low at $572.4 million in Q1 2022.
- The 5-year median for Receivables is $698.0 million (2024), against an average of $684.2 million.
- The sharpest annual moves came in 2022 and 2025: Receivables surged 38.27% in 2022, then retreated 7.65% in 2025.
- Jazz Pharmaceuticals' Receivables stood at $651.5 million in 2022, then advanced by 8.33% to $705.8 million in 2023, then gained by 1.55% to $716.8 million in 2024, then advanced by 15.9% to $830.7 million in 2025, then gained by 0.67% to $836.3 million in 2026.
- Business Quant data shows JAZZ's Receivables at $836.3 million in Q1 2026, $830.7 million in Q4 2025, and $764.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 880.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 880.90 Mn |
| Mar 31, 2026 | 836.30 Mn |
| Dec 31, 2025 | 830.70 Mn |
| Sep 30, 2025 | 764.36 Mn |
| Jun 30, 2025 | 714.00 Mn |
| Mar 31, 2025 | 652.99 Mn |
| Dec 31, 2024 | 716.77 Mn |
| Sep 30, 2024 | 723.64 Mn |
| Jun 30, 2024 | 698.04 Mn |
| Mar 31, 2024 | 707.10 Mn |
| Dec 31, 2023 | 705.79 Mn |
| Sep 30, 2023 | 627.84 Mn |
| Jun 30, 2023 | 610.39 Mn |
| Mar 31, 2023 | 623.94 Mn |
| Dec 31, 2022 | 651.49 Mn |
| Sep 30, 2022 | 601.18 Mn |
| Jun 30, 2022 | 594.03 Mn |
| Mar 31, 2022 | 572.39 Mn |
| Dec 31, 2021 | 563.36 Mn |
| Sep 30, 2021 | 499.02 Mn |